These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1433 related articles for article (PubMed ID: 21262990)

  • 1. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
    Heidenreich PA; Trogdon JG; Khavjou OA; Butler J; Dracup K; Ezekowitz MD; Finkelstein EA; Hong Y; Johnston SC; Khera A; Lloyd-Jones DM; Nelson SA; Nichol G; Orenstein D; Wilson PW; Woo YJ; ; ; ; ; ; ; ; ; ; ; ; ;
    Circulation; 2011 Mar; 123(8):933-44. PubMed ID: 21262990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association.
    Dunbar SB; Khavjou OA; Bakas T; Hunt G; Kirch RA; Leib AR; Morrison RS; Poehler DC; Roger VL; Whitsel LP;
    Circulation; 2018 May; 137(19):e558-e577. PubMed ID: 29632217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association.
    Kazi DS; Elkind MSV; Deutsch A; Dowd WN; Heidenreich P; Khavjou O; Mark D; Mussolino ME; Ovbiagele B; Patel SS; Poudel R; Weittenhiller B; Powell-Wiley TM; Joynt Maddox KE;
    Circulation; 2024 Jul; 150(4):e89-e101. PubMed ID: 38832515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association.
    Ovbiagele B; Goldstein LB; Higashida RT; Howard VJ; Johnston SC; Khavjou OA; Lackland DT; Lichtman JH; Mohl S; Sacco RL; Saver JL; Trogdon JG;
    Stroke; 2013 Aug; 44(8):2361-75. PubMed ID: 23697546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.
    Heidenreich PA; Albert NM; Allen LA; Bluemke DA; Butler J; Fonarow GC; Ikonomidis JS; Khavjou O; Konstam MA; Maddox TM; Nichol G; Pham M; Piña IL; Trogdon JG; ; ; ; ; ;
    Circ Heart Fail; 2013 May; 6(3):606-19. PubMed ID: 23616602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct medical costs of hospitalizations for cardiovascular diseases in Shanghai, China: trends and projections.
    Wang S; Petzold M; Cao J; Zhang Y; Wang W
    Medicine (Baltimore); 2015 May; 94(20):e837. PubMed ID: 25997060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of chronic cardiovascular disease for major insurers.
    Trogdon JG; Finkelstein EA; Nwaise IA; Tangka FK; Orenstein D
    Health Promot Pract; 2007 Jul; 8(3):234-42. PubMed ID: 17606951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association.
    Joynt Maddox KE; Elkind MSV; Aparicio HJ; Commodore-Mensah Y; de Ferranti SD; Dowd WN; Hernandez AF; Khavjou O; Michos ED; Palaniappan L; Penko J; Poudel R; Roger VL; Kazi DS;
    Circulation; 2024 Jul; 150(4):e65-e88. PubMed ID: 38832505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review.
    Gheorghe A; Griffiths U; Murphy A; Legido-Quigley H; Lamptey P; Perel P
    BMC Public Health; 2018 Aug; 18(1):975. PubMed ID: 30081871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.
    Stevens W; Peneva D; Li JZ; Liu LZ; Liu G; Gao R; Lakdawalla DN
    BMC Health Serv Res; 2016 May; 16():175. PubMed ID: 27165638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the aging population on coronary heart disease in the United States.
    Odden MC; Coxson PG; Moran A; Lightwood JM; Goldman L; Bibbins-Domingo K
    Am J Med; 2011 Sep; 124(9):827-33.e5. PubMed ID: 21722862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Impact of Moderate-Vigorous Physical Activity Among Those With and Without Established Cardiovascular Disease: 2012 Medical Expenditure Panel Survey.
    Valero-Elizondo J; Salami JA; Osondu CU; Ogunmoroti O; Arrieta A; Spatz ES; Younus A; Rana JS; Virani SS; Blankstein R; Blaha MJ; Veledar E; Nasir K
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27604455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the cost of cardiovascular disease.
    Tarride JE; Lim M; DesMeules M; Luo W; Burke N; O'Reilly D; Bowen J; Goeree R
    Can J Cardiol; 2009 Jun; 25(6):e195-202. PubMed ID: 19536390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of cardiovascular diseases in the United Kingdom.
    Luengo-Fernández R; Leal J; Gray A; Petersen S; Rayner M
    Heart; 2006 Oct; 92(10):1384-9. PubMed ID: 16702172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future incidence, prevalence and costs of stroke in the UK.
    King D; Wittenberg R; Patel A; Quayyum Z; Berdunov V; Knapp M
    Age Ageing; 2020 Feb; 49(2):277-282. PubMed ID: 31957781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model.
    Abushanab D; Al-Badriyeh D; Marquina C; Liew D; Al-Zaidan M; Ghaith Al-Kuwari M; Abdulmajeed J; Ademi Z
    Diabetes Obes Metab; 2024 Jan; 26(1):148-159. PubMed ID: 37845584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs.
    Yazdanyar A; Newman AB
    Clin Geriatr Med; 2009 Nov; 25(4):563-77, vii. PubMed ID: 19944261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical care costs among patients with established cardiovascular disease.
    Nichols GA; Bell TJ; Pedula KL; O'Keeffe-Rosetti M
    Am J Manag Care; 2010 Mar; 16(3):e86-e93. PubMed ID: 20205493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Grover SA; Coupal L; Zowall H
    Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeled Health and Economic Impact of Team-Based Care for Hypertension.
    Dehmer SP; Baker-Goering MM; Maciosek MV; Hong Y; Kottke TE; Margolis KL; Will JC; Flottemesch TJ; LaFrance AB; Martinson BC; Thomas AJ; Roy K
    Am J Prev Med; 2016 May; 50(5 Suppl 1):S34-S44. PubMed ID: 27102856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.